Astria Therapeutics Inc (ATXS) Stock: A Closer Look at the Market Potential

Company’s 36-month beta value is 0.72.Analysts have differing opinions on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”

The public float for ATXS is 44.51M, and currently, short sellers hold a 4.52% ratio of that floaft. The average trading volume of ATXS on April 04, 2024 was 1.03M shares.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

ATXS) stock’s latest price update

The stock price of Astria Therapeutics Inc (NASDAQ: ATXS) has plunged by -5.47 when compared to previous closing price of 12.80, but the company has seen a -10.57% decline in its stock price over the last five trading sessions. 24/7 Wall Street reported 2023-12-31 that As the year wound to a close, biotechs were in focus among the notable insider purchases.

ATXS’s Market Performance

ATXS’s stock has fallen by -10.57% in the past week, with a monthly drop of -15.15% and a quarterly rise of 55.33%. The volatility ratio for the week is 7.46% while the volatility levels for the last 30 days are 9.20% for Astria Therapeutics Inc The simple moving average for the last 20 days is -17.40% for ATXS stock, with a simple moving average of 36.27% for the last 200 days.

Analysts’ Opinion of ATXS

Many brokerage firms have already submitted their reports for ATXS stocks, with Evercore ISI repeating the rating for ATXS by listing it as a “Outperform.” The predicted price for ATXS in the upcoming period, according to Evercore ISI is $18 based on the research report published on March 28, 2023 of the previous year 2023.

ATXS Trading at -12.13% from the 50-Day Moving Average

After a stumble in the market that brought ATXS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -28.40% of loss for the given period.

Volatility was left at 9.20%, however, over the last 30 days, the volatility rate increased by 7.46%, as shares sank -12.64% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +36.26% upper at present.

During the last 5 trading sessions, ATXS fell by -10.57%, which changed the moving average for the period of 200-days by +18.86% in comparison to the 20-day moving average, which settled at $14.56. In addition, Astria Therapeutics Inc saw 57.55% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at ATXS starting from Morabito Christopher, who sale 10,000 shares at the price of $13.59 back on Apr 01 ’24. After this action, Morabito Christopher now owns 0 shares of Astria Therapeutics Inc, valued at $135,939 using the latest closing price.

PERCEPTIVE ADVISORS LLC, the Director of Astria Therapeutics Inc, purchase 2,481,350 shares at $12.09 during a trade that took place back on Feb 01 ’24, which means that PERCEPTIVE ADVISORS LLC is holding 4,873,721 shares at $29,999,522 based on the most recent closing price.

Stock Fundamentals for ATXS

The total capital return value is set at -0.28. Equity return is now at value -31.40, with -30.04 for asset returns.

Based on Astria Therapeutics Inc (ATXS), the company’s capital structure generated 0.0 points at debt to capital in total, while cash flow to debt ratio is standing at -208.04. The debt to equity ratio resting at 0.0. The interest coverage ratio of the stock is 29.43.

Currently, EBITDA for the company is -67.83 million with net debt to EBITDA at 2.59. The liquidity ratio also appears to be rather interesting for investors as it stands at 21.73.

Conclusion

In a nutshell, Astria Therapeutics Inc (ATXS) has experienced a mixed performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts